TYRA-300 is a next generation investigational FGFR inhibitor that is designed to focus solely on the FGFR3 receptor, aiming to provide the potential benefits of FGFR inhibition to patients with ...

Gain-of-function mutations in fibroblast growth factor receptor (FGFR ... underscores the critical role of FGFR3 in regulating bone repair and suggests that FGFR antagonists could become a ...

Gain-of-function mutations in fibroblast growth factor receptor (FGFR ... underscores the critical role of FGFR3 in regulating bone repair and suggests that FGFR antagonists could become a ...

Erdafitinib is a pan–fibroblast growth factor receptor (FGFR) inhibitor approved for the treatment of locally advanced or metastatic urothelial carcinoma in adults with susceptible FGFR3/2 ...

Erdafitinib inhibits FGFR, a family of receptor tyrosine kinases that promote uncontrolled growth of urothelial carcinomas. Alterations in the FGFR3 gene are found in 15%-20% of advanced ...

Genescience Pharmaceuticals Co. Ltd. has identified fibroblast growth factor receptor 2 (FGFR2) and/or FGFR3 inhibitors reported to be useful for the treatment of cancer, osteochondrodysplasia and ...

fibroblast growth factor receptor (FGFR) mutations are known to be drivers of bladder cancer development and progression. "In 2016, we published studies showing that the tumors with FGFR3 ...

TYRA-300 is an investigational, oral, FGFR3-selective inhibitor ... are due to a mutation in the fibroblast growth factor receptor (FGFR) 3 gene. The disorder is characterized by short stature ...

Tyra develops molecules targeting the fibroblast growth factor receptor (FGFR). Its lead asset is TYRA-300, which targets FGFR3 and will start a phase 2 trial in Achondroplasia. It will also begin ...

TYRA-300 is a next generation investigational FGFR inhibitor, that is designed to focus solely on the FGFR3 receptor, aiming to provide the potential benefits of FGFR inhibition to patients with ...

selective pan-fibroblast growth factor receptor (FGFR) tyrosine kinase inhibitor, received FDA accelerated approval to treat locally advanced or metastatic urothelial cancer in adults with FGFR3/2 ...

Insilico Medicine Inc. has synthesized fibroblast growth factor receptor 2 (FGFR2) and/or FGFR3 inhibitors reported to be useful for the treatment of cancer.